Endocrine hormone therapies, including ovarian function suppression, selective estrogen receptor modulators, selective estrogen receptor down regulators, and aromatase inhibitors, are commonly used as primary systemic therapies in patients with ER+/PR+ breast cancer, complementing surgery (12, 13). The gene discussed is PGR; the disease is breast cancer.